http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 07:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html <p>Kamada Ltd. (NASDAQ: KMDA) announced that the U.S. Food and Drug Administration has approved the company's new in-house Rapid Fluorescent Focus Inhibition Test laboratory for rabies virus neutralization testing.</p> <p>The laboratory is located at Kamada's manufacturing plant in Beit Kama, Israel, and will conduct potency testing for the company's KEDRAB and KAMRAB anti-rabies products. The facility represents one of a limited number of laboratories worldwide capable of performing such specialized tests.</p> <p>The RFFIT test serves as the standard method for measuring rabies-neutralizing antibody levels and will be used throughout all manufacturing steps of KEDRAB and KAMRAB, from plasma collection to final product http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html Mon, 01 Jun 2026 07:02:00 -0400 A.05001876 A.17150087 KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html <p>Kamada Ltd. (NASDAQ: KMDA) announced that the U.S. Food and Drug Administration has approved the company's new in-house Rapid Fluorescent Focus Inhibition Test laboratory for rabies virus neutralization testing.</p> <p>The laboratory is located at Kamada's manufacturing plant in Beit Kama, Israel, and will conduct potency testing for the company's KEDRAB and KAMRAB anti-rabies products. The facility represents one of a limited number of laboratories worldwide capable of performing such specialized tests.</p> <p>The RFFIT test serves as the standard method for measuring rabies-neutralizing antibody levels and will be used throughout all manufacturing steps of KEDRAB and KAMRAB, from plasma collection to final product http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html Mon, 01 Jun 2026 07:02:00 -0400 A.05001876 A.17150087 KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html <p>Kamada Ltd. (NASDAQ: KMDA) announced that the U.S. Food and Drug Administration has approved the company's new in-house Rapid Fluorescent Focus Inhibition Test laboratory for rabies virus neutralization testing.</p> <p>The laboratory is located at Kamada's manufacturing plant in Beit Kama, Israel, and will conduct potency testing for the company's KEDRAB and KAMRAB anti-rabies products. The facility represents one of a limited number of laboratories worldwide capable of performing such specialized tests.</p> <p>The RFFIT test serves as the standard method for measuring rabies-neutralizing antibody levels and will be used throughout all manufacturing steps of KEDRAB and KAMRAB, from plasma collection to final product http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html Mon, 01 Jun 2026 07:02:00 -0400 A.05001876 A.17150087 KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html <p>Kamada Ltd. (NASDAQ: KMDA) announced that the U.S. Food and Drug Administration has approved the company's new in-house Rapid Fluorescent Focus Inhibition Test laboratory for rabies virus neutralization testing.</p> <p>The laboratory is located at Kamada's manufacturing plant in Beit Kama, Israel, and will conduct potency testing for the company's KEDRAB and KAMRAB anti-rabies products. The facility represents one of a limited number of laboratories worldwide capable of performing such specialized tests.</p> <p>The RFFIT test serves as the standard method for measuring rabies-neutralizing antibody levels and will be used throughout all manufacturing steps of KEDRAB and KAMRAB, from plasma collection to final product http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html Mon, 01 Jun 2026 07:02:00 -0400 A.05001876 A.17150087 KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html <p>Kamada Ltd. (NASDAQ: KMDA) announced that the U.S. Food and Drug Administration has approved the company's new in-house Rapid Fluorescent Focus Inhibition Test laboratory for rabies virus neutralization testing.</p> <p>The laboratory is located at Kamada's manufacturing plant in Beit Kama, Israel, and will conduct potency testing for the company's KEDRAB and KAMRAB anti-rabies products. The facility represents one of a limited number of laboratories worldwide capable of performing such specialized tests.</p> <p>The RFFIT test serves as the standard method for measuring rabies-neutralizing antibody levels and will be used throughout all manufacturing steps of KEDRAB and KAMRAB, from plasma collection to final product http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html Mon, 01 Jun 2026 07:02:00 -0400 A.05001876 A.17150087 KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html <p>Kamada Ltd. (NASDAQ: KMDA) announced that the U.S. Food and Drug Administration has approved the company's new in-house Rapid Fluorescent Focus Inhibition Test laboratory for rabies virus neutralization testing.</p> <p>The laboratory is located at Kamada's manufacturing plant in Beit Kama, Israel, and will conduct potency testing for the company's KEDRAB and KAMRAB anti-rabies products. The facility represents one of a limited number of laboratories worldwide capable of performing such specialized tests.</p> <p>The RFFIT test serves as the standard method for measuring rabies-neutralizing antibody levels and will be used throughout all manufacturing steps of KEDRAB and KAMRAB, from plasma collection to final product http://www.streetinsider.com/FDA/Kamada+receives+FDA+approval+for+rabies+testing+laboratory/26578959.html Mon, 01 Jun 2026 07:02:00 -0400 A.05001876 A.17150087 KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Press+Releases/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html <p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.</p> <p align="justify">The new laboratory is part of Kamada’s Quality Control laboratory network and represents a significant expansion of the Company’s advanced testing http://www.streetinsider.com/Globe+Newswire/Kamada+Announces+FDA+Approval+of+its+New+In-House+Rabies+Virus+Neutralization+Testing+Laboratory/26578925.html Mon, 01 Jun 2026 07:00:00 -0400 A.05001876 A.17150087 KMDA KMDA O.06119155 O.15356844 O.34929518 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++KAMADA+LTD++++++++++++++++For%3A+Jun+01/26578927.html si-local-file:///var/storage/secattach/20260601/26578927.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++KAMADA+LTD++++++++++++++++For%3A+Jun+01/26578927.html Mon, 01 Jun 2026 07:00:00 -0400 KMDA KMDA O.06119155 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++KAMADA+LTD++++++++++++++++For%3A+Jun+01/26578927.html si-local-file:///var/storage/secattach/20260601/26578927.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++KAMADA+LTD++++++++++++++++For%3A+Jun+01/26578927.html Mon, 01 Jun 2026 07:00:00 -0400 KMDA KMDA O.06119155 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++KAMADA+LTD++++++++++++++++For%3A+Jun+01/26578927.html si-local-file:///var/storage/secattach/20260601/26578927.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++KAMADA+LTD++++++++++++++++For%3A+Jun+01/26578927.html Mon, 01 Jun 2026 07:00:00 -0400 KMDA KMDA O.06119155 http://www.streetinsider.com/Analyst+Comments/Kamada+%28KMDA%29+Reiterated+at+Buy+by+Benchmark+After+Q1+Results/26517348.html <p>Benchmark analyst Robert Wasserman reiterated a Buy rating and $15.00 price target on Kamada Ltd. (NASDAQ: KMDA).</p><p>The analyst commented, "Kamada Ltd. reported below-expected financial results for their 1Q26, including revenues of $45.2 million (3% growth) and net income of $0.07, as compared to revenues of $44.0 million and EPS of $0.07 in 1Q25. Our estimates had been revenues of $47.5 million (8% growth) and net income of $0.11 per share. The culprit in the lower 1Q26 results were proprietary product revenues, which decreased to $36.2 million from $40.0 million in the prior year and $38.2 million in the previous quarter, http://www.streetinsider.com/Analyst+Comments/Kamada+%28KMDA%29+Reiterated+at+Buy+by+Benchmark+After+Q1+Results/26517348.html Tue, 19 May 2026 07:43:02 -0400 KMDA http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Kamada+Ltd.+%28KMDA%29/26489532.html <p>H.C. Wainwright analyst Andrew S. Fein reiterated a Buy rating and $13.00 price target on Kamada Ltd. (NASDAQ: KMDA).</p><p>The analyst commented: "Kamada’s 1Q26 update reinforces our view that the company remains on track to deliver double-digit top-line growth in 2026, with management reaffirming full-year 2026 guidance despite a temporary $2.4M shipment delay that impacted 1Q revenue and was subsequently resolved in April. Management reiterated 2026 guidance of $200M to $205M in revenue and $50M to $53M in adjusted EBITDA, supported by continued underlying demand across the company’s core commercial portfolio, including KEDRAB in the U.S. and KAMRAB and VARIZIG in http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Kamada+Ltd.+%28KMDA%29/26489532.html Thu, 14 May 2026 06:49:07 -0400 KMDA